Avoro Capital Advisors LLC - Q3 2017 holdings

$1.29 Billion is the total value of Avoro Capital Advisors LLC's 45 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 45.7% .

 Value Shares↓ Weighting
IMMU BuyIMMUNOMEDICS INC$206,058,000
+122.5%
14,739,461
+40.5%
15.98%
+36.7%
FOLD BuyAMICUS THERAPEUTICS INC$97,072,000
+62.5%
6,437,122
+8.5%
7.53%
-0.2%
KITE SellKITE PHARMA INC$89,363,000
+6.8%
496,983
-38.4%
6.93%
-34.4%
ARRY BuyARRAY BIOPHARMA INC$65,842,000
+88.4%
5,353,029
+28.2%
5.11%
+15.7%
CLVS BuyCLOVIS ONCOLOGY INC$64,742,000
+391.4%
785,700
+458.4%
5.02%
+202.0%
MDCO BuyMEDICINES CO$63,723,000
+51.2%
1,720,393
+55.1%
4.94%
-7.1%
ASND BuyASCENDIS PHARMAsponsored adr$59,309,000
+115.6%
1,636,124
+65.1%
4.60%
+32.5%
BMRN BuyBIOMARIN PHARMACEUTICAL INC$55,653,000
+22.4%
597,972
+19.4%
4.32%
-24.8%
PCRX BuyPACIRA PHARMACEUTICALS INC$49,245,000
+121.6%
1,311,460
+181.5%
3.82%
+36.1%
HZNP NewHORIZON PHARMA PLC$44,584,0003,516,100
+100.0%
3.46%
MRTX BuyMIRATI THERAPEUTICS INC$43,414,000
+422.7%
3,710,601
+63.1%
3.37%
+221.0%
AVXS NewAVEXIS INC$42,242,000436,702
+100.0%
3.28%
DERM BuyDERMIRA INC$41,040,000
+6.3%
1,520,000
+14.7%
3.18%
-34.7%
ZGNX NewZOGENIX INC$35,974,0001,026,368
+100.0%
2.79%
GBT BuyGLOBAL BLOOD THERAPEUTICS INC$34,910,000
+48.4%
1,124,300
+30.7%
2.71%
-8.8%
IOVA BuyIOVANCE BIOTHERAPEUTICS INC$32,560,000
+6.7%
4,201,343
+1.2%
2.52%
-34.5%
ASMB BuyASSEMBLY BIOSCIENCES INC$31,678,000
+152.7%
907,162
+49.4%
2.46%
+55.2%
TLGT BuyTELIGENT INC$30,720,000
-18.7%
4,578,230
+10.8%
2.38%
-50.1%
TSRO SellTESARO INC$25,186,000
-55.0%
195,092
-51.3%
1.95%
-72.4%
NewINTEC PHARMA LTD$19,652,0002,195,705
+100.0%
1.52%
VNDA BuyVANDA PHARMACEUTICALS INC$17,690,000
+20.3%
988,270
+9.5%
1.37%
-26.1%
AVEO SellAVEO PHARMACEUTICALS INC$17,543,000
+19.1%
4,806,249
-27.5%
1.36%
-26.8%
MYOK NewMYOKARDIA INC$17,063,000398,207
+100.0%
1.32%
CPRX BuyCATALYST PHARMACEUTICALS INC$11,682,000
+11.2%
4,635,745
+21.8%
0.91%
-31.7%
AGEN SellAGENUS INC$10,847,000
-12.9%
2,459,554
-22.7%
0.84%
-46.5%
ARGX BuyARGENX SEsponsored adr$9,713,000
+112.4%
429,600
+99.3%
0.75%
+30.5%
BCRX SellBIOCRYST PHARMACEUTICALS INC$9,319,000
-14.2%
1,778,525
-9.0%
0.72%
-47.3%
ALIM BuyALIMERA SCIENCES INC$8,426,000
+2.9%
6,241,581
+5.9%
0.65%
-36.8%
FOLD BuyAMICUS THERAPEUTICS INCcall$8,400,000
+1478.9%
3,000,000
+1100.0%
0.65%
+873.1%
VCYT BuyVERACYTE INC$8,217,000
+8.7%
936,909
+3.2%
0.64%
-33.3%
DBVT NewDBV TECHNOLOGIES S Asponsored adr$8,216,000193,600
+100.0%
0.64%
CASC  CASCADIAN THERAPEUTICS INC$7,449,000
+10.1%
1,821,2480.0%0.58%
-32.3%
IMMU NewIMMUNOMEDICS INCcall$6,300,000875,000
+100.0%
0.49%
VIVE BuyVIVEVE MEDICAL INC$5,414,000
-5.2%
1,033,276
+29.9%
0.42%
-41.7%
 PERNIX THERAPEUTICS HOLDINGS INCconvertible debt$2,526,000
+35.9%
6,000,0000.0%0.20%
-16.6%
CLLS SellCELLECTIS S Asponsored ads$2,227,000
+0.7%
78,289
-8.6%
0.17%
-38.0%
OVAS BuyOVASCIENCE INC$1,593,000
+225.8%
1,121,952
+258.1%
0.12%
+100.0%
ARRY  ARRAY BIOPHARMA INCcall$1,500,000
+155.5%
500,0000.0%0.12%
+56.8%
ONS  ONCOBIOLOGICS INC$936,000
+36.8%
683,5310.0%0.07%
-15.1%
FENC NewFENNEC PHARMACEUTICALS INC$731,00066,666
+100.0%
0.06%
SPY NewSPDR S&P 500 ETFput$469,000250,000
+100.0%
0.04%
ONSIW  ONCOBIOLOGICS INC - WARRANT Awarrant$28,000
-30.0%
233,3330.0%0.00%
-60.0%
ONSIZ  ONCOBIOLOGICS INC - WARRANT Bwarrant$12,000
-45.5%
233,3330.0%0.00%
-66.7%
MDCO ExitMEDICINES COcall$0-200,000
-100.0%
-0.01%
SRNE ExitSORRENTO THERAPEUTICS INC$0-416,230
-100.0%
-0.10%
ExitNEURODERM LTD$0-44,516
-100.0%
-0.17%
ExitSPDR S&P 500 ETFput$0-250,000
-100.0%
-0.18%
AXGT ExitAXOVANT SCIENCES LTD$0-82,087
-100.0%
-0.24%
PTCT ExitPTC THERAPEUTICS$0-120,000
-100.0%
-0.28%
FBIO ExitFORTRESS BIOTECH INC$0-603,657
-100.0%
-0.36%
NVRO ExitNEVRO CORP$0-50,000
-100.0%
-0.47%
SGMO ExitSANGAMO THERAPEUTICS INC$0-800,000
-100.0%
-0.89%
NBIX ExitNEUROCRINE BIOSCIENCES INC$0-219,500
-100.0%
-1.28%
AERI ExitAERIE PHARMACEUTICALS INC$0-230,842
-100.0%
-1.53%
ACAD ExitACADIA PHARMACEUTICALS INC$0-614,200
-100.0%
-2.16%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2017-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
AMICUS THERAPEUTICS INC36Q3 202317.9%
MIRATI THERAPEUTICS INC.35Q3 202317.2%
BIOMARIN PHARMACEUTICAL INC31Q3 20238.0%
SAREPTA THERAPUTICS INC28Q3 202314.8%
ASCENDIS PHARMA28Q3 20239.1%
ARGENX SE26Q3 20239.5%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%
FENNEC PHARMACEUTICALS INC25Q3 20230.4%
MADRIGAL PHARMACEUTICALS INC22Q3 20237.2%
XENON PHARMACEUTICALS INC22Q3 20233.3%

View Avoro Capital Advisors LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Avoro Capital Advisors LLC Q3 2017 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Adverum Biotechnologies, Inc.Sold outFebruary 14, 202300.0%
DICE Therapeutics, Inc.February 14, 20232,525,5555.3%
IOVANCE BIOTHERAPEUTICS, INC.February 14, 20237,020,0004.4%
IVERIC bio, Inc.February 14, 20236,750,0005.0%
Kura Oncology, Inc.February 14, 20233,105,0004.5%
Aadi Bioscience, Inc.September 26, 20222,849,40211.7%
ARENA PHARMACEUTICALS INCFebruary 11, 20221,235,0002.0%
AVADEL PHARMACEUTICALS PLCFebruary 11, 20221,670,0002.9%
FENNEC PHARMACEUTICALS INC.February 11, 20221,200,0004.6%
POINT Biopharma Global Inc.Sold outFebruary 11, 202200.0%

View Avoro Capital Advisors LLC's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G/A2024-04-23
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Avoro Capital Advisors LLC's complete filings history.

Compare quarters

Export Avoro Capital Advisors LLC's holdings